OS Therapies Targets September Approval for Osteosarcoma Drug with FDA Filing

Rockville, Tuesday, 3 February 2026.
The company initiated its regulatory filing for OST-HER2. Approval by September would secure a Priority Review Voucher, recently valued at $200 million, adding significant financial upside.